Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.

Also called NCT05610566

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05610566
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05610566. Allocation not applicable; no masking; primary purpose treatment. Start 2022-07-06 (actual); primary completion 2025-07-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China
Condition
Mitral Regurgitation
Intervention (Device)
the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System
Lead sponsor
Peijia Medical Technology (Suzhou) Co., Ltd. (class: industry)
Collaborator
West China Hospital (class: other)
Collaborator
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)
Collaborator
The Second Affiliated Hospital of Harbin Medical University (class: other)

Record details

Record id
cardio:ct-nct05610566
Content hash
f5f0fc1a3631da473f17648a01e04974928cbbc76aa7e895d94c56c17d883769